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Constrictive pericarditis (CP) and restrictive cardiomyopathy share many similarities in both their clinical and hemodynamic
characteristics and N-terminal prohormone brain natriuretic peptide (NT-proBNP) is a sensitive marker of cardiac diastolic
dysfunction. The objectives of the present study were to determine whether serum NT-proBNP was high in patients with
endomyocardial fibrosis (EMF) and CP, and to investigate how this relates to diastolic dysfunction. Thirty-three patients were divided into
two groups: CP (16 patients) and EMF (17 patients). The control group consisted of 30 healthy individuals. Patients were evaluated by
bidimensional echocardiography, with restriction syndrome evaluated by pulsed Doppler of the mitral flow and serum NT-proBNP
measured by immunoassay and detected by electrochemiluminescence. Spearman correlation coefficient was used to analyze the
association between log NT-proBNP and echocardiographic parameters. Log NT-proBNP was significantly higher (P < 0.05) in CP
patients (log mean: 2.67 pg/mL; 95%CI: 2.43-2.92 log pg/mL) and in EMF patients (log mean: 2.91 pg/mL; 95%CI: 2.70-3.12 log pg/mL)
compared with the control group (log mean: 1.45; 95%CI: 1.32-1.60 log pg/mL). There were no statistical differences between EMF and
CP patients (P = 0.689) in terms of NT-proBNP. The NT-proBNP log tended to correlate with peak velocity of the E wave (r = 0.439; P
= 0.060, but not with A wave (r = -0.399; P = 0.112). Serum NT-proBNP concentration can be used as a marker to detect the presence
of diastolic dysfunction in patients with restrictive syndrome; however, serum NT-proBNP levels cannot be used to differentiate restrictive
cardiomyopathy from CP.
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Introduction
Restrictive heart disease may be caused by disorders
of any of the 3 layers of the heart. Constrictive pericarditis
(CP) and restrictive cardiomyopathy share many similari-
ties in both their clinical and hemodynamic characteristics.
In patients with any of these anomalies, the main physi-
ologic characteristic is a disturbance in the filling and the
relaxation of the heart (1).
Pericardial disorders leading to diastolic heart failure
are usually in the form of constrictive physiology (2). Myo-
cardial disorders include a broad range of pathologies
leading to restrictive physiology. Endomyocardial fibrosis
(EMF) is a prototype of restrictive cardiomyopathy leading
to diastolic dysfunction and preserved systolic function (3).
It is difficult to diagnose diastolic heart failure accu-
rately in restrictive syndromes. Doppler echocardiography
is the most readily available and useful noninvasive meth-
od for assessing diastolic dysfunction in these patients (4).
Measuring serum N-terminal prohormone brain natriuretic
peptide (NT-proBNP) and brain natriuretic peptide (BNP)
are useful methods for diagnosing heart failure (5). These
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peptides are sensitive markers of cardiac diastolic dys-
function and measuring them may be useful as an early
diagnostic tool in restrictive syndromes (4).
The purpose of this study was to determine whether
serum NT-proBNP levels are elevated in patients reporting
restrictive syndromes, as well as to investigate how this
relates to echocardiographic indices of diastolic dysfunc-
tion.
Subjects and Methods
Thirty-three patients underwent prospective, consecu-
tive evaluations from 2003 to 2005 in the cardiomyopathy
group of Heart Institute of the University of São Paulo.
Patients were divided into two groups: CP (16 patients, 7
females, age range 16-71 years old, mean 32 ± 16 years);
EMF (17 patients, 14 females, age range 28-63 years old,
mean 49 ± 9 years). A control group consisted of 30
healthy individuals who did not report any heart disease
(15 females, age range 36-56 years old, mean 44 ± 5).
After initial clinical evaluation, echocardiography and
magnetic resonance imaging (MRI) were used to charac-
terize disease in patients reporting pericardial thickening.
The following exclusion criteria were followed: serum creati-
nine >1.4 mg/dL, left ventricular systolic dysfunction (ejec-
tion fraction <55%, assessed by echocardiography,
Teichholz method), atrial fibrillation, pregnancy, and obe-
sity (BMI >30 kg/m2).
The echocardiographic study was carried out with pa-
tients in the left lateral and dorsal decubitus position using
Acuson (Sequoia 512, USA), equipped with a 2.5–4.0-MHz
multifrequency transducer. Full echocardiographic studies
were carried out with at least 3 measures for each variable,
and means were calculated for each value. M-mode indi-
ces were obtained in compliance with the American Socie-
ty of Echocardiography (6).
Mitral flow was measured with an apical 4-chamber
view using pulsed-wave Doppler, with sample volume
placed on the edge of the valvular leaflets with a decrease
in the gain and filter for better definition of the flow. E and A
waves peak velocity as well as the E/A ratio were meas-
ured. For the analysis of respiratory variation of mitral flow
velocity, the E wave mean was obtained from 3 heart
cycles in inspiration and 3 cycles in expiration. The percen-
tile variation was calculated based on these mean values.
The reference variation value was 25%. CP diagnosis was
confirmed by MRI findings of pericardial thickening of more
than 4 mm (7).
The diagnosis of EMF was established on the basis of
the following echocardiographic findings present in all
patients: obliteration of the ventricular apex, atrial dilation,
an increase in endocardial echo reflectivity, and atrioven-
tricular regurgitation (8). Patients with atrial fibrillation were
excluded.
NT-proBNP was determined by collecting peripheral
blood from the forearm into a dry tube kept in ice and
centrifuged at 10 to 3000 rpm while refrigerated. After the
serum was separated, NT-proBNP levels were measured
by immunoassay and detected by electrochemilumines-
cence (Roche Diagnostics, Brazil) using 20 µL serum and
polyclonal antibodies that detect epitopes in the N-terminal
region (amino acids 1-76) of the proBNP (108 amino
acids). The assay is fully automated using the Elecsys
2010 automated analyzer (Roche Diagnostics).
The coefficient of variation for the NT-proBNP assay
was 7.0% (mean concentration 57 pg/mL) and the inter-
and intra-assay variations were 4.0 and 2.6%, respective-
ly; concentration ranged from 5 up to 35,000 pg/mL (data
from the manufacturer). The threshold (lower limit of detec-
tion) was 5 pg/mL
Cross-reactivity with other natriuretic peptides (BNP,
proANP1, CNP2) as well as the angiotensins was <0.001%
(data from the manufacturer).
ANOVA and the Bonferroni test were used to analyze
log differences of NT-proBNP between groups. Spearman
correlation coefficient was used to analyze the association
between log NT-proBNP and echocardiographic param-
eters (E and A waves velocity peaks, and the E/A ratio). A
P value <0.05 was considered to be statistically significant.
All patients signed a written consent form to participate
in the study after being instructed about the objectives and
methods of the study. The procedures were performed
according to the recommendations of the Institutional Eth-
ics Review board, which approved the protocol based on
the principles defined by the Helsinki Declaration.
Results
For CP, diagnosis was secondary to tuberculosis in 2
patients; in all others, it was idiopathic. Symptoms reported
included dyspnea on effort (9 patients), increased abdomi-
nal volume with ascites (5 patients), and edema in the
lower limbs (6 patients). All CP patients underwent sur-
gery, except one, whose death occurred while the patient
awaited clinical compensation before surgery.
The distribution of functional class in endomyocardial
fibrosis patients according to the New York Heart Associa-
tion (NYHA) criteria was as follows: class I for 10 patients
and class II for 7 patients.
NT-proBNP
Log serum NT-proBNP was statistically increased (P <
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0.05) in CP, with a log mean of 2.67 pg/mL (95%CI: 2.43-
2.92 log pg/mL), and EMF with a log mean of 2.91 (95%CI:
2.70-3.12 log pg/mL) compared with the control group, log
mean of 1.45 pg/mL (95%CI: 1.32-1.60 log pg/mL). No
statistically significant difference was detected in log se-
rum NT-proBNP values between EMF and CP patients (P
= 0.689). Log serum NT-proBNP tended to correlate with
echocardiographic parameter E wave peak velocity (r =
0.439; P = 0.060; Table 1).
Discussion
The data reported here showed that patients with re-
strictive physiology (CP and EMF) had higher serum NT-
proBNP levels compared with controls.
Few studies have been published investigating an
association of natriuretic factor levels and pericardial dis-
eases and most of them have focused on atrial natriuretic
factor. These studies report increases in serum atrial natri-
uretic factor after surgical correction of tamponade and
CP. This increase could be explained by the fact that
pericardial diseases may cause atrial distensibility restric-
tion, thus limiting atrial natriuretic factor secretion and
reducing its diuretic and natriuretic effects (9,10).
Lubien et al. (11) reported that, in the absence of left
ventricular (LV) systolic dysfunction, plasma BNP levels
were significantly higher in patients with LV diastolic dys-
function assessed with echocardiography than in subjects
without LV diastolic dysfunction. Plasma BNP levels were
markedly higher in the subgroup of patients with impaired
relaxation than in controls (202 vs 33 pg/mL).
The encasement of the heart by rigid, nonpliable peri-
cardium results in characteristic pathophysiologic effects,
including impaired diastolic filling of the ventricles, exag-
gerated ventricular interdependence and dissociation of
intracardiac and intrathoracic pressures during respira-
tion. CP typically presents chronic insidious signs and
symptoms of predominantly systemic venous congestion
(12). We believe that diastolic dysfunction secondary to
pericardial effusion and pericardial constriction might be
associated with an increase in NT-proBNP serum levels.
Computed tomography and MRI have been used to
measure pericardial thickness. However, these methods
provide only anatomic information without hemodynamic
physiology. The finding of a thickened pericardium does
not necessarily indicate CP (13). In pericardial constric-
tion, classic surgery is indicated for cases involving clinical
heart failure. For such a condition, intervention must not be
postponed, because patients in advanced functional class
(IV in NYHA criteria) have higher mortality rates (30-40%
vs 6-19%) and lower benefits. Improvement in symptoms
and normalization of cardiac pressures may occur within a
few months after pericardiectomy (14). As for patients in
functional class I with no clinical signs of heart failure,
pericardiectomy is not to be recommended (9).
The present study demonstrates that patients with
pericardial constriction who are symptomatic have in-
creased serum NT-proBNP levels and patients with EMF
who have mild symptoms also have an increase in NT-
proBNP levels. The determination of serum NT-proBNP
might be one more complementary method useful for the
follow-up of early cases of pericardial thickening when
patients do not yet have signs or symptoms of heart fail-
ure. We did not observe differences in the causes of CP,
although only analysis of a greater number of patients
can elucidate this fact.
EMF is characterized by a fairly normal appearance of
the myocardium, but the stiffness of the ventricle is mark-
edly increased due to thickening and scarring of the en-
docardium leading to slow relaxation of the underlying
myocardium. The LV fibrotic involvement may decrease
diastolic suction and restrict the increase of end-diastolic
volume, which reduces ventricular filling and hinders the
Frank-Starling mechanism (3,8). The fibrous involvement
of the endocardium and myocardium adjacent to the apex
and inflow of both ventricles causes a restrictive syndrome
characteristic of the disease. Usually, the fibrotic tissue
involves the papillary muscles, leading to additional atrio-
ventricular valvular dysfunctions that, combined with re-
striction of ventricular filling, cause the clinical manifesta-
tions of the disease. The overall systolic function of the left
ventricle is usually preserved, except in advanced forms.
The occurrence of EMF is supposedly restricted to
tropical zones. Recent studies, however, have reported a
universal distribution of this disease, contrary to the pre-
ceding statement (3,8).
CP and restrictive cardiomyopathy create a diagnostic
problem primarily because of the many similarities in
both their clinical and hemodynamic presentations (15)
Table 1. Association between log NT-proBNP and echocardio-
graphic parameters.
Measures Spearman correlation P
E wave 0.439 0.060
A wave -0.399 0.112
DT -0.144 0.554
IVRT 0.1165 0.392
The Spearman correlation coefficients are presented in the
Table. E wave = peak wave of early mitral inflow; A wave = peak
wave of late mitral inflow; DT = deceleration time; IVRT =
isovolumic relaxation time.
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requiring careful attention to hemodynamic and Doppler
echocardiographic features (2). In recent years, new di-
agnostic techniques have become available to differenti-
ate the causes of diastolic dysfunction from each other
(16).
Few studies have determined the efficacy of BNP
measurements to differentiate CP from restrictive cardio-
myopathy. Leya et al. (17) measured BNP levels in 6
patients with CP and 5 patients with restrictive cardiomy-
opathy (172.2 ± 825.8 vs 128.0 ± 52.7 pg/mL, respectively)
and concluded that BNP levels were significantly elevated
in restrictive cardiomyopathy compared with those in CP
and might be a useful non-invasive marker for the differen-
tiation of the two conditions. On the other hand, we did not
observe differences in NT-proBNP levels between CP and
restrictive cardiomyopathy. However, all patients with EMF
were mildly symptomatic.
Echocardiography is the imaging modality most often
used for the initial evaluation of pericardial disease, espe-
cially in patients suspected of effusion and tamponade (1).
Doppler echocardiography is the most non-invasive meas-
urement used to assess diastolic dysfunction in these
patients. The natriuretic peptides (BNP or NT-proBNP)
may be useful for detecting patients with diastolic dysfunc-
tion especially in those patients with a restrictive filling
pattern (4).
This study confirms that the restrictive filling pattern of
transmitral flow velocity is a marker of more severe heart
failure, as indicated by its association with higher NT-
proBNP levels in restrictive syndromes. Serum NT-proBNP
may be useful for identifying those patients with more
severe diastolic heart failure (4,18).
References
1. Goldstein JA. Cardiac tamponade, constrictive pericarditis,
and restrictive cardiomyopathy. Curr Probl Cardiol 2004;
29: 503-567.
2. Kabbani SS, LeWinter MM. Diastolic heart failure. Constric-
tive, restrictive, and pericardial. Cardiol Clin 2000; 18: 501-
509.
3. Mady C, Salemi VM, Ianni BM, Fernandes F, Arteaga E.
Relation between left atrial dimension and exercise capacity
in endomyocardial fibrosis. Arq Bras Cardiol 2005; 84: 222-
224.
4. Dahlstrom U. Can natriuretic peptides be used for the diag-
nosis of diastolic heart failure? Eur J Heart Fail 2004; 6: 281-
287.
5. Wei T, Zeng C, Chen L, Chen Q, Zhao R, Lu G, et al.
Bedside tests of B-type natriuretic peptide in the diagnosis
of left ventricular diastolic dysfunction in hypertensive pa-
tients. Eur J Heart Fail 2005; 7: 75-79.
6. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommenda-
tions regarding quantitation in M-mode echocardiography:
results of a survey of echocardiographic measurements.
Circulation 1978; 58: 1072-1083.
7. Appleton CP, Jensen JL, Hatle LK, Oh JK. Doppler evalua-
tion of left and right ventricular diastolic function: a technical
guide for obtaining optimal flow velocity recordings. J Am
Soc Echocardiogr 1997; 10: 271-292.
8. Mady C, Barretto AC, Mesquita ET, Silva PR, Cardoso RH,
Bellotti G, et al. Maximal functional capacity in patients with
endomyocardial fibrosis. Eur Heart J 1993; 14: 240-242.
9. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA,
Harris PC. Pathogenesis of edema in constrictive pericardi-
tis. Studies of body water and sodium, renal function, hemo-
dynamics, and plasma hormones before and after peri-
cardiectomy. Circulation 1991; 83: 1880-1887.
10. Panayiotou H, Haitas B, Hollister AS. Atrial wall tension
changes and the release of atrial natriuretic factor on relief
of cardiac tamponade. Am Heart J 1995; 129: 960-967.
11. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J,
Kazanegra R, et al. Utility of B-natriuretic peptide in detect-
ing diastolic dysfunction: comparison with Doppler velocity
recordings. Circulation 2002; 105: 595-601.
12. Myers RB, Spodick DH. Constrictive pericarditis: clinical
and pathophysiologic characteristics. Am Heart J 1999;
138: 219-232.
13. Giorgi B, Mollet NR, Dymarkowski S, Rademakers FE,
Bogaert J. Clinically suspected constrictive pericarditis: MR
imaging assessment of ventricular septal motion and con-
figuration in patients and healthy subjects. Radiology 2003;
228: 417-424.
14. Hoit BD. Management of effusive and constrictive pericar-
dial heart disease. Circulation 2002; 105: 2939-2942.
15. Yazdani K, Maraj S, Amanullah AM. Differentiating constric-
tive pericarditis from restrictive cardiomyopathy. Rev Cardi-
ovasc Med 2005; 6: 61-71.
16. Mertens LL, Denef B, de Geest H. The differentiation be-
tween restrictive cardiomyopathy and constrictive pericardi-
tis: the impact of the imaging techniques. Echocardiography
1993; 10: 497-508.
17. Leya FS, Arab D, Joyal D, Shioura KM, Lewis BE, Steen LH,
et al. The efficacy of brain natriuretic peptide levels in differ-
entiating constrictive pericarditis from restrictive cardiomy-
opathy. J Am Coll Cardiol 2005; 45: 1900-1902.
18. Yu CM, Sanderson JE, Shum IO, Chan S, Yeung LY, Hung
YT, et al. Diastolic dysfunction and natriuretic peptides in
systolic heart failure. Higher ANP and BNP levels are asso-
ciated with the restrictive filling pattern. Eur Heart J 1996;
17: 1694-1702.
